Celebrex News and Research RSS Feed - Celebrex News and Research

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer. It has the brand name Celebrex and Celebra (in other countries) for arthritis and Onsenal for polyps. Celecoxib is available by prescription in capsule form.
Researchers create combination drug that controls both tumor growth and metastasis

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread. [More]
U.S. Court awards Teva favorable decision for generic Celebrex

U.S. Court awards Teva favorable decision for generic Celebrex

Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day "first-to-file" exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules. [More]
Actavis' subsidiary files lawsuit against FDA over Celebrex decision

Actavis' subsidiary files lawsuit against FDA over Celebrex decision

Actavis plc today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. [More]
Mylan challenges FDA's decision regarding generic drug marketing exclusivity on Celecoxib Capsules

Mylan challenges FDA's decision regarding generic drug marketing exclusivity on Celecoxib Capsules

Mylan Inc. today announced that it has filed suit against the U.S. Food and Drug Administration, challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer's Celebrex. [More]
Aspirin can lower colon cancer risk among people with high levels of specific gene

Aspirin can lower colon cancer risk among people with high levels of specific gene

The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene. [More]
Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Nonsteroidal antinflamatory drugs (NSAIDs) that block an enzyme called COX-2 relieve pain and inflammation but can cause heart attacks, stroke, heart failure, and even sudden cardiac death. [More]
Certain drugs in Obamacare plans carry hefty pricetags

Certain drugs in Obamacare plans carry hefty pricetags

Insurers selling Obamacare plans have set drug prices according to a tiered system that in some cases requires consumers to pay as much as 50 percent of the cost, The Associated Press writes. [More]
First Edition: March 24, 2013

First Edition: March 24, 2013

Today's early morning highlights from the major news organizations examine the final week for health law enrollment, the Supreme Court case this week about the law's contraceptive mandate and the fourth anniversary of the enactment of the controversial overhaul. [More]
People with intermittent explosive disorder elevate levels of markers of systemic inflammation in blood

People with intermittent explosive disorder elevate levels of markers of systemic inflammation in blood

People with intermittent explosive disorder — a psychiatric illness characterized by impulsivity, hostility and recurrent aggressive outbursts — have elevated levels of two markers of systemic inflammation in their blood, according to a study involving nearly 200 subjects. [More]
Cells sticking molecule over-produced in rheumatoid arthritis and cancers

Cells sticking molecule over-produced in rheumatoid arthritis and cancers

A molecule that helps cells stick together is significantly over-produced in two very different diseases - rheumatoid arthritis and a variety of cancers, including breast and brain tumors, concludes a new study. The scientists who made the discovery also found candidate drugs to inhibit the molecule, cadherin-11, one of which is already in a clinical trial. [More]
New study could lead to better and more targeted drugs for arthritis and cancer

New study could lead to better and more targeted drugs for arthritis and cancer

The increased risk of heart attack or stroke associated with many arthritis drugs may be avoidable, according to a new international study co-authored by researchers at Imperial College London. [More]
Institut de France awards 2013 Grand Prix Scientifique to Penn Medicine researcher

Institut de France awards 2013 Grand Prix Scientifique to Penn Medicine researcher

Garret FitzGerald MD, FRS, chairman of the Pharmacology Department and director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, has been awarded the 2013 Grand Prix Scientifique by the Institut de France. [More]
Duration of ibuprofen use may reduce risk of bladder cancer in northern New England patients

Duration of ibuprofen use may reduce risk of bladder cancer in northern New England patients

Dartmouth researchers have found that duration of ibuprofen use was associated with a reduced risk of bladder cancer in patients in northern New England, which has a high mortality rate of this disease. In a 2012 collaborative project with the National Cancer Institute, Margaret Karagas, PhD, co-director, Cancer Epidemiology & Chemoprevention program at Norris Cotton Cancer Center, and Professor of Community and Family Medicine at the Geisel School of Medicine at Dartmouth, and Richard Waddell, D.Sc, Research Assistant Professor of Medicine at the Geisel School of Medicine, looked for connections between ibuprofen use and bladder cancer. [More]

Train-Match-Fit-Streamline uses 11 factors to quickly pair likely drugs and diseases

With the cost of putting a single new drug on the pharmacy shelves topping a staggering $1 billion, scientists are reporting development of a way to determine if an already-approved drug might be used to treat a different disease. The technique for repurposing existing medicines could cut drug development costs and make new medicine available to patients faster, they report in ACS' Journal of Medicinal Chemistry. [More]
Lead 8A analog can treat osteosarcoma in children

Lead 8A analog can treat osteosarcoma in children

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer. [More]
Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it. [More]
Positive results from CrystalGenomics’ CG100649 Phase 2b OA study

Positive results from CrystalGenomics’ CG100649 Phase 2b OA study

CrystalGenomics, Inc., a biopharmaceutical company headquartered in Korea, has just announced positive results from the Phase 2b osteoarthritis (OA) study of the CG100649, CrystalGenomics' next-generation NSAID candidate. [More]
Decreasing GPA adherence among COX-2 users increases risk of upper GI complications

Decreasing GPA adherence among COX-2 users increases risk of upper GI complications

To relieve pain, arthritis sufferers are prescribed medications that may include non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors, both of which can irritate the digestive tract. At times additional drugs are co-prescribed with NSAIDs or COX-2 inhibitors to prevent adverse gastrointestinal (GI) effects. [More]

International study into safety of NSAIDs reaches enrollment milestone

An international study into the safety of some of the most widely used medicines has reached a significant milestone by recruiting its 6,000th patient. [More]
Preliminary results from CINJ's Celebrex and Lipitor Phase II combination trial on prostrate cancer

Preliminary results from CINJ's Celebrex and Lipitor Phase II combination trial on prostrate cancer

Research from The Cancer Institute of New Jersey (CINJ) on the FDA-approved drugs Celebrex and Lipitor -- used respectively for arthritis pain and lowering cholesterol -- shows that these drugs are well tolerated in the treatment of recurrent prostate cancer. [More]